# An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

> **NCT01894984** · — · TERMINATED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 640 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Oral atypical anti-psychotic

## Key facts

- **NCT ID:** NCT01894984
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 640 (ACTUAL)
- **Why stopped:** The study was terminated because of high dropout rate.
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894984, "An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01894984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*